Cancer Research Center, Sanford-Burnham Institute for Medical Research, La Jolla, California 92037, USA.
J Biol Chem. 2012 Dec 7;287(50):42009-18. doi: 10.1074/jbc.M112.371153. Epub 2012 Oct 24.
The membrane PTK7 pseudokinase, a component of both the canonical and noncanonical/planar cell polarity Wnt pathways, modulates cell polarity and motility in biological processes as diverse as embryo development and cancer cell invasion. To determine the individual proteolytic events and biological significance of the ectodomain shedding in the PTK7 function, we used highly invasive fibrosarcoma HT1080 cells as a model system. Current evidence suggested a likely link between PTK7 shedding and cell invasion in our HT1080 cell model system. We also demonstrated that in HT1080 cells the cleavage of the PTK7 ectodomain by an ADAM proteinase was coupled with the membrane type-1 matrix metalloproteinase (MT1-MMP) cleavage of the PKP(621)↓LI site in the seventh Ig-like domain of PTK7. Proteolytic cleavages led to the generation of two soluble, N-terminal and two matching C-terminal, cell-associated fragments of PTK7. This proteolysis was a prerequisite for the intramembrane cleavage of the C-terminal fragments of PTK7 by γ-secretase. γ-Secretase cleavage was predominantly followed by the efficient decay of the resulting C-terminal PTK7 fragment via the proteasome. In contrast, in HT1080 cells, which overexpressed the C-terminal PTK7 fragment, the latter readily entered the nucleus. Our data imply that therapeutic inhibition of PTK7 shedding may be used to slow cancer progression.
膜 PTK7 假激酶是经典和非经典/平面细胞极性 Wnt 途径的组成部分,在胚胎发育和癌细胞侵袭等多种生物学过程中调节细胞极性和运动。为了确定 PTK7 功能中细胞外结构域脱落的个体蛋白水解事件和生物学意义,我们使用高度侵袭性纤维肉瘤 HT1080 细胞作为模型系统。目前的证据表明,在我们的 HT1080 细胞模型系统中,PTK7 脱落与细胞侵袭之间可能存在关联。我们还证明,在 HT1080 细胞中,ADAM 蛋白酶对 PTK7 细胞外结构域的切割与膜型 1 基质金属蛋白酶(MT1-MMP)对 PTK7 第七个免疫球蛋白样结构域中 PKP(621)↓LI 位点的切割相关。蛋白水解切割导致生成两个可溶性的、N 端和两个匹配的 C 端、细胞相关的 PTK7 片段。这种蛋白水解是 γ-分泌酶对内源性切割 PTK7 C 端片段的先决条件。γ-分泌酶切割主要伴随着蛋白酶体对产生的 C 端 PTK7 片段的有效降解。相比之下,在过度表达 C 端 PTK7 片段的 HT1080 细胞中,后者很容易进入细胞核。我们的数据表明,抑制 PTK7 脱落的治疗可能用于减缓癌症进展。